|Bid||67.30 x 800|
|Ask||67.31 x 1300|
|Day's range||66.65 - 68.24|
|52-week range||56.56 - 78.94|
|Beta (5Y monthly)||0.40|
|PE ratio (TTM)||280.29|
|Earnings date||28 Jul 2021 - 02 Aug 2021|
|Forward dividend & yield||2.84 (4.26%)|
|Ex-dividend date||14 Jun 2021|
|1y target est||74.61|
Dr. Anand Swaminathan, Emergency Medicine Physician in New Jersey, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.
Investors expecting Gilead Sciences to license Arcus Biosciences' lead asset could be in for an unpleasant surprise.
FOSTER CITY, Calif., June 24, 2021--Gilead Sciences, Inc. (Nasdaq: GILD) today announced interim results from the Phase 2b and Phase 3 clinical trials evaluating the first-in-class entry inhibitor Hepcludex® (bulevirtide) for the treatment of chronic hepatitis delta virus (HDV). Findings from the Phase 3 study support the safety and efficacy profile of bulevirtide 2 mg once daily and are being presented today as a late-breaker in the International Liver Congress™ (ILC) 2021 Official Press Progra